Biocon, Ltd.’s repurposed anti-CD6 IgG1 monoclonal antibody itolizumab is now available as part of the treatment armamentarium against COVID-19 in India.
Itolizumab injection 25mg/5mL has now received authorization from the Drugs Controller General of India for restricted emergency use in the treatment of cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS)